HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?

Similar documents
Interventions to Prevent Age- Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer s-type Dementia

Mild Cognitive Impairment (MCI)

Nutritional intervention in early Alzheimer s disease. Sasha Newsam, PhD Global Medical Affairs Manager Nutricia

Effective Health Care Program

SHARED CARE OF MCI/EARLY DEMENTIA

ILSI Europe Satellite Workshop on Nutrition for the Ageing Brain: Towards Evidence for an Optimal Diet

RESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH

Practical Matters in the Care of A Person with Dementia

Section Editor Steven T DeKosky, MD, FAAN Kenneth E Schmader, MD

Mary Sano, PhD Mount Sinai School of Medicine James J Peters Veterans Affairs Hospital June 15, 2013

Mild cognitive impairment A view on grey areas of a grey area diagnosis

Form D1: Clinician Diagnosis

Mild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for Clinical Practice. Hypothesized Key Players in the Pathogenesis of AD

Diagnosis and Treatment of Alzhiemer s Disease

Alzheimer s Disease (AD) and Dietary Supplementation George C. SPATHARAKIS

Alzheimer s Disease Update: From Treatment to Prevention

Erin Cullnan Research Assistant, University of Illinois at Chicago

Cognitive ageing and dementia: The Whitehall II Study

Drug Update. Treatments for Cognitive Impairment in the Older Adult. William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle

How can the new diagnostic criteria improve patient selection for DM therapy trials

Mild Cognitive Impairment

Exercise and Lifestyle Factors Can cognitive decline & dementia be prevented? Henry Brodaty

Can aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators

As people age, changes to the structure

Mild Cognitive Impairment in the General Population: Occurrence and progression to Alzheimer s disease

THE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME

Dementia and Cognition in Older Adults: Year in Review

COGNITIVE ALTERATIONS IN CHRONIC KIDNEY DISEASE K K L E E

B-Vitamins and the Ageing Brain

ANTIOXIDANT SUPPLEMENTS IN ALZHEIMER S DEMENTIA AND MILD COGNITIVE IMPAIRMENT: A SYSTEMATIC REVIEW

EBM Journal Club: Does Ginkgo Biloba improve memory in elder group

The Diagnosis and Management of Mild Cognitive Impairment A Clinical Review

Secrets of delaying aging and living disease free Part 1

Neurocognitive Disorders Research to Emerging Therapies

Memory Care Monthly. Supporting Healthcare Professionals in Caring for the Aging November / December 2008

Moving Targets: An Update on Diagnosing Dementia in the Clinic

Alzheimer's Disease Brain Failure, Stopping the Momentum. Katherine E. Galluzzi, DO, CMD, FACOFP dist.

Cognitive Screening in Risk Assessment. Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University.

#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by

Preventing Cognitive Decline and Dementia A Way Forward

L APPROCCIO NUTRIZIONALE AL MILD COGNITIVE IMPAIRMENT

Dietary Supplements, Caffeine, and Cognitive Aging

The added value of the IWG-2 diagnostic criteria for Alzheimer s disease

Mild Cognitive Impairment

Approccio nutraceutico alla gestione del declino cognitivo iniziale

Changing diagnostic criteria for AD - Impact on Clinical trials

Anxiety, Depression, and Dementia/Alzheimer Disease: What are the Links?

Statins and Cognition A Focus on Mechanisms

Understanding the potential of cognitive ingredients. Dr Carrie Ruxton Freelance Dietitian

Stephen Salloway, M.D., M.S. Disclosure of Interest

Objective 4/22/2019. Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation.

Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation

10/19/2017. Cognitive changes of normal aging What is normal, what is not? Dementia, Alzheimer s what s the difference?

Regulatory Challenges across Dementia Subtypes European View

AT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE

Current and Future Strategies in Alzheimer s Disease Treatment & Prevention

tdcs in Clinical Disorders

Can we prevent Alzheimer s disease and other memory disorders?

DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT

Literature Scan: Alzheimer s Drugs

Coconut Oil, Vitamins and Alzheimer s: What Really Works?

DEMENTIA, THE BRAIN AND HOW IT WORKS AND WHY YOU MATTER

Trail making test A 2,3. Memory Logical memory Story A delayed recall 4,5. Rey auditory verbal learning test (RAVLT) 2,6

The current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease

Partner logo here. Can Alzheimer s disease be prevented? Henry Brodaty

11/12/2018. Acknowledgements. Risk factors for Alzheimer s disease

Post Stroke Cognitive Decline

Vascular and Degenerative Causes of Cognitive Impairment: How are they linked?

Depression: An Important Risk Factor for Cognitive Decline

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient

Imaging of Alzheimer s Disease: State of the Art

Nutrition and Water for Dementia Prevention

UNIVERSITY OF WESTERN ONTARIO

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

NEUROPSYCHOMETRIC TESTS

September 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research

Alzheimer s Disease. Fact Sheet. Fact Sheet. Fact Sheet. What Causes AD?

Mild cognitive impairment beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

Diagnosis and management of non-alzheimer dementias. Melissa Yu, M.D. Department of Neurology

Author's response to reviews

Alzheimer s Disease without Dementia

Could physical activity delay cognitive decline in older adults with vascular risk factors? The AIBL active study

Alzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms. l The diagnosis of AD l Neuropsychiatric symptoms l Place of the ICT

What We Can Do To Prevent or Reduce the Risk for Dementia

ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health

Can lifestyle prevent Alzheimer s disease? Henry Brodaty

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future

Neuropsychiatric symptoms as predictors of MCI and dementia: Epidemiologic evidence

CONSULTATION DRAFT NATIONAL PREVENTIVE HEALTH RESEARCH STRATEGY ( )

Part 2: Early detection, assessment and treatment in relation to the new guidelines. Christopher Patterson McMaster University

15/10/2018. A Functional Approach to Neurodegeneration. Functional Medicine for Alzheimer s Patients. Belinda Reynolds B.Sc.Nut.Diet.

Cognitive impairment and falls. Dr Morag Taylor NSW Falls Network Webinar 21 August 2018

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Biomarkers for Alzheimer s disease

Neuropsychological Evaluation of

Brain Health and Risk Factors for Dementia

A Dynamic Model of Care for Late Onset Cognitive Impairment. Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong

Why Cognition Matters: Impact of Cognitive Impairment on Safety and Independent Living Skills

Transcription:

EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Sofia Duque Orthogeriatric Unit São Francisco Xavier Hospital Occidental Lisbon Hospital Center University Geriatric Unit, Faculty of Medicine of Lisbon Geriatric Study Group, Portuguese Society of Internal Medicine

CONFLICT OF INTEREST DISCLOSURE I have the following potential conflicts of interest to report: - Received lecture fees from Nestlé Health Science and Nutricia

Outline Definition of MCI Etiology of MCI Impact of MCI Interventions to prevent cognitive decline at MCI

Definition of MCI Cognitive Continuum 10-25% Impairment of ADL Normal Age-related cognitive decline Mild cognitive impairment Dementia Prodromal stage of Dementia

Definition of MCI Cognitive complaint, cognitive decline or impairment Objective evidence of impairment in cognitive domains: memory, executive function/attention, language, or visuospatial skills (<1.5 SD) Essentially normal functional activities Absence of dementia Petersen RC et al. Arch Neurol. 1999; 56:303 308. Petersen RC. J Intern Med. 2004; 256:183 194.Petersen RC et al. Arch Neurol. 2009; 66:1447 1455.

Definition of MCI MCI phenotype Petersen RC. J Intern Med. 2004; 256:183 194.Petersen RC et al. Arch Neurol. 2009; 66:1447 1455.

Etiology of MCI Roberts R. Clin Geriatr Med. 2013;29:753-72.

Etiology of MCI Petersen RC. Alzheimers Dement. 2005;1:5-10

Impact of MCI Trajectories of MCI Risk factors Protective factors Normal Age-related cognitive decline Mild cognitive impairment Dementia 20-40% Risk factors for progression to dementia 20-40% 10-15 % per year (control 1-2%) Roberts R. Clin Geriatr Med. 2013;29:753-72.

Impact of MCI Prognosis of MCI Annual rates of conversion from MCI to dementia over 48 months MCI AlzhD 12%/year Peterson RC et al. Arch Neurol. 1999;56:303-8.

Impact of MCI RF for progression to dementia Older age ApoE4 Worse baseline cognition Stroke Hypertension T2 Diabetes Low education Multi-domain MCI Amnestic MCI Impairment in IADL (Subclinical) Depression Neuropsychiatric symptoms Anticholinergic drugs Lower serum folates White matter hyperintensity volume (MRI) Atrophy (MRI) Hippocampal atrophy (MRI) FDG PET pattern of Alzheimer s disease CSF markers compatible with Alzheimer's disease Positive amyloid imaging scan Roberts R. Clin Geriatr Med. 2013;29:753-72. Peterson RC et al. Arch Neurol. 2009; 66: 1447 1455. Cooper C et al. Am J Psychiatry. 2015;172:323-34.

MILD COGNITIVE IMPAIRMENT risk of DEMENTIA Public Health Issue INTERVENTIONS Geda YE. Curr Psychiatry Rep. 2012;14:320-7.

Interventions to prevent cognitive decline at MCI Goal of Interventions Revert MCI to normal cognition Revert MCI to better cognition Stop progression of MCI Delay progression of MCI Stop progression to Dementia

Interventions to prevent cognitive decline at MCI How to prevent cognitive decline at MCI stage? How to prevent PROGRESSION OF MCI TO DEMENTIA?

Interventions to prevent cognitive decline at MCI Some facts. Most studies about prevention of cognitive decline are in persons with normal cognition baseline Main outcome of most studies is cognitive performance (and not dementia incidence) Several studies in MCI pts consider as positive result any improvement in cognitive performance at short-term Long term effect? Proxy for delay of MCI progression into dementia?

Interventions to prevent cognitive decline at MCI Some studies Several interventions Small studies Short term studies High risk of bias Inconsistent and changing classifications

Interventions to prevent cognitive decline at MCI Effectiveness of interventions to prevent or delay cognitive decline Main outcome: Dementia incidence Secondary outcomes: Cognitive performance Randomized & nonrandomized controlled trials Prospective observational cohort studies (>500 pts) > 6 months follow-up excluded high risk of bias studies Publications until September 2016 9448 references 263 studies 25 on MCI Agency Healthcare Research & Quality (US). Comparative Effectiveness Reviews,188. March 2017

Interventions to prevent cognitive decline at MCI 13 interventions Cognitive training Physical activity Nutraceuticals Diet interventions Multimodal interventions Hormone therapy Vitamins Antihypertensive drugs Lipid lowering drugs NSAIDs Antidementia drugs Diabetes treatment Other interventions AHRQ (US). Comparative Effectiveness Reviews, 2017. 188

Interventions to prevent cognitive decline at MCI 13 interventions Cognitive training Physical activity Nutraceuticals Diet interventions Multimodal interventions Hormone therapy Vitamins Antihypertensive drugs Lipid lowering drugs NSAIDs Antidementia drugs Diabetes treatment Other interventions AHRQ (US). Comparative Effectiveness Reviews, 2017. 188

Cognitive Training Promotion of neuroplasticity Building new neuronal pathways Maintaining existing neuronal pathways

Interventions to prevent cognitive decline at MCI Cognitive Training Trials n time mode Intervention Trained domains Result Buschert, 2012 24 28 months Small group (12pp) 2 hours/week, 6 weeks Mnemonic memory 2/6 cognitive tests Dementia Rapp, 2002 19 6 months Small group 2 hours/week, 6 weeks Memory Self-rated memory cognitive tests Vidovich, 2015 160 24 months Small group (6-9 pp) 3 hours/week 5 weeks Attention Memory Executive functions 1/9 cognitive tests Kwok, 2012 223 12 months Small group (3-5 pp) 1,5 hours/week 12 weeks Attention Processing speed Memory, Reasoning cognitive tests Herrera, 2012 22 6 months Individual Computer-based 2 hours/week, 12 weeks Recognition Working memory Recall Mixed results 3/9 cognitive tests AHRQ (US). Comparative Effectiveness Reviews, 2017. 188

Interventions to prevent cognitive decline at MCI Cognitive Training AHRQ (US). Comparative Effectiveness Reviews, 2017. 188

Physical activity Neuroprotection neuronal connectivity brain volume B amyloid Cerebrovascular reserve blood viscosity brain blood flow Chronic & Psychiatric Disorders

Interventions to prevent cognitive decline at MCI Physical activity Trials n time Mode / Training Result Baker, 2010 33 6 months Aerobic exercise cognitive tests (executive fx, women) Hildreth, 2015 53 6 months Aerobic / endurance No improvement of cognitive tests Nagamatsu, 2012 86 26 weeks Resistance (vs aerobic vs balance&tone) Suzuki, 2013 100 6 months Multicomponent physical activity cognitive tests (executive fx, women) No improvement of cognitive tests Suzuki, 2012 50 6 months 12 months Multicomponent physical activity 2/9 cognitive tests at 6 months (MMSE, Memory, Verbal Fluency) (no improvement at 12 months) Lautenschlager, 2008 100 6 M training 18 M follow-up Home-based physical activity 1/5 cognitive tests (ADAS-Cog at 6&18M) Dementia incidence AHRQ (US). Comparative Effectiveness Reviews, 2017. 188

Interventions to prevent cognitive decline at MCI Physical activity Effects of aerobic exercise on mild cognitive impairment a controlled trial Improvement of language and executive functions Baker LD et al. Arch Neurol. 2010;67(1):71-9

Interventions to prevent cognitive decline at MCI Physical activity Effects of multicomponent exercise on cognitive function in older adults with amnestic mild cognitive impairment Multicomponent exercise (n=25) vs Education control group (n=25) Improvement of MMSE, memory and executive functions P=0.04 P=0.03 P=0.02 Suzuki T et al. PLoS One. 2013;8:e61483.

Nutraceuticals oxidative stress inflammation vascular fx Supplementation of macronutrients of brain tissue and fx

Interventions to prevent cognitive decline at MCI Nutraceuticals Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI) a 12-month randomised, double-blind, placebo-controlled trial MCI 60 yo Fish oil group (daily omega-3 fatty acids) 12 months memory executive fx = MMSE Placebo Lee LK et al. Psychopharmacology (Berl). 2013;225(3):605-12.

Interventions to prevent cognitive decline at MCI Nutraceuticals Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms a randomized, placebo-controlled, double-blind, multi-center trial attention executive fx processing speed Gavrilova SI et al. Int J Geriatr Psychiatry. 2014;29:1087-95

Interventions to prevent cognitive decline at MCI Nutraceuticals Ginkgo biloba for Prevention of Dementia: A Randomized Controlled Trial DeKosky ST et al. JAMA. 2008;300:2253-62.

Hormone therapy Epidemiological studies suggest benefit of HRT

Interventions to prevent cognitive decline at MCI Hormone therapy Testosterone treatment of men with MCI and low serum testosterone Soybean in Elderly Japanese Subjects with Memory Complaints verbal memory (1/14 tests) Cherrier MM et l. Am J Alzheimers Dis Other Demen. 2015;30(4):421-30. MMSE (1/6 tests) Kato-Kataoka A et l. J Clin Biochem Nutr. 2010; 47: 246 255

Vitamins Neurotropic vitamins Lowering of homocysteine levels (B)

Interventions to prevent cognitive decline at MCI Vitamins Vitamin E n=516, 3 years follow up B Vitamins Folic acid + B12 + B6 n=266, 2 years follow up Multivitamin (E + C) Improvement of MMSE and memory tests limited to pts w/ hyperhomocysteinemia No effect in dementia incidence Vitamin E had no benefit in patients with mild cognitive impairment. Petersen RC et al. N Engl J Med. 2005;352:2379-88 de Jager CA et al. Int J Geriatr Psychiatry. 2012;27:592-600 Improvement of MMSE in both arms, no difference between multivitamins and placebo Naeini AM et al. Eur J Nutr. 2014;53:1255-62.

Antidementia drugs

Interventions to prevent cognitive decline at MCI Antidementia drugs Donepezil reduces progression to dementia at 1 year but not at 3 years (at 3 years only in ApoE4 carriers) Petersen RC et al. N Engl J Med. 2005;352:2379-88

Interventions to prevent cognitive decline at MCI Antidementia drugs Rivastigmine failed to reduce progression to dementia at 4 years Feldman HH et al. Lancet Neurol. 2007;6:501-12

There is very little evidence that AchEI affect progression to dementia or cognitive test scores in MCI. AchEI should not be recommended for MCI. Russ T et al. Cochrane Database of Systematic Reviews. 2012;12(9)

Diabetes treatment

Interventions to prevent cognitive decline at MCI Diabetes treatment Pioglitazone in older adults with MCI and insulin resistance n=78, 6 months follow up Metformin in older adults with Amnestic MCI and BMI n=80, 1 year follow up visual memory (1/10 tests) memory (1/10 tests) Hildreth KL et al. Dement Geriatr Cogn Dis Extra. 2015; 5: 51 63. Luchsinger JA et al. J Alzheimers Dis. 2016; 51: 501 514.

Multimodal interventions Cognitive decline is a multifactorial condition and can be prevented by multifactorial interventions

Interventions to prevent cognitive decline at MCI Multimodal interventions Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial The multidomain intervention and polyunsaturated fatty acids, either alone or in combination, had no significant effects on cognitive decline over 3 years in elderly people with memory complaints Vellas B et al. J Prev Alz Dis 2014;1:13-22. Andrieu S et al. Lancet Neurol. 2017;16:377-389

Interventions to prevent cognitive decline at MCI Multimodal interventions A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER) a randomised controlled trial Ngandu T et al. Lancet. 2015;385(9984):2255-63.

Interventions to prevent cognitive decline at MCI There is no strong evidence that any intervention can prevent cognitive decline in MCI patients. Agency Healthcare Research & Quality (US). Comparative Effectiveness Reviews,188. March 2017

Is there really nothing to do to prevent cognitive decline at MCI? Be careful with trials results Late stage interventions (life cycle approach urgent) Short time interventions Short follow-up Heterogeneity of studies prevent reliable meta-analysis Control groups might not be real-life persons - More education, healthier behaviors, less comorbidity - Received some kind of intervention Are not trials underestimating the effectiveness of interventions?...

Interventions to prevent cognitive decline at MCI Wrap up conclusions, into Clinical Practice Interventions Cognition Progression to dementia Cognitive Training Physical activity Clinical Practice Some benefit??? Promote! Training several cognitive domains Some benefit??? Promote! Multicomponent exercise Omega-3 Scarce benefit??? Not to prescribe Gingko biloba Scarce benefit No benefit Not to prescribe Testosterone / Soybean / Vitamins Antidementia drugs Scarce benefit No benefit /??? Not to prescribe Scarce benefit Scarce benefit Not to prescribe

Take Home Messages Mild cognitive impairment is a prodromal stage of dementia It is a priority to stop progression to dementia and to revert to normal cognition In theory several interventions could work but high risk of bias of trials might underestimate effectiveness Prevention of Mild cognitive impairment is the best treatment.

EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Thank your for your attention! Sofia Duque sofia.b.duque@gmail.com